Is Compounded Semaglutide Still Legal and Safe in 2026?

Semaglutide is the active ingredient in two FDA-approved brand-name medications: Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management). Both are manufactured by Novo Nordisk as sterile, prefilled auto-injector pens using semaglutide in its base form, the same molecular structure studied in clinical trials.

Compounded semaglutide refers to semaglutide that is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. Instead of the brand-name auto-injector, compounded versions typically come as a multi-dose vial with a separate needle and syringe, or as an auto-injector filled by the compounding pharmacy. Patients self-administer the injection subcutaneously, the same general method as Wegovy.

Compounding pharmacies operate under two regulatory frameworks relevant to this discussion. 503A pharmacies are traditional compounding pharmacies that prepare medications for individual patients based on a specific prescription. They are regulated primarily by state pharmacy boards. 503B facilities, also called outsourcing facilities, are registered with the FDA, operate under cGMP (current Good Manufacturing Practice) standards, and can produce larger batches without a patient-specific prescription. They are subject to FDA inspections and are held to significantly higher sterility and quality standards than 503A pharmacies.

The legal authority for compounding pharmacies to produce semaglutide at all depended on a specific FDA mechanism: the drug shortage list. When a drug is on the shortage list, federal law permits both 503A and 503B compounders to prepare that drug, even if it is otherwise prohibited (as it would be for a commercially available branded drug). That shortage designation is what made compounded semaglutide legal, and its removal is what put the industry in its current uncertain state.

The short answer: it depends, on who is doing the compounding, what state you are in, and what litigation has resolved or not resolved by the time you are reading this.

Here is what is documented as of our last review:

How the legal basis worked. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can legally produce drugs that appear on the FDA's drug shortage list. From 2022 through early 2025, both Wegovy and Ozempic were on that list due to persistent supply constraints that left patients unable to fill prescriptions.

The shortage resolution. In early 2025, the FDA announced it had removed semaglutide from the drug shortage database, finding that Novo Nordisk's supply had recovered sufficiently to meet demand. Under a normal reading of the law, this removal would prohibit 503A and 503B compounders from continuing to produce semaglutide, because the shortage exemption no longer applies.

The litigation response. Multiple compounding pharmacy associations and telehealth companies challenged the FDA's shortage determination in federal court, arguing the shortage was not fully resolved in practice and that patients had been abruptly cut off from affordable access. As of mid-2026, the legal proceedings have created uncertainty about enforcement timelines and which compounders are operating legally versus in violation of FDA guidance. Some 503B outsourcing facilities had ceased semaglutide production following the FDA's notice; others continued operating under the protection of litigation-related stays.

State-level variation. State pharmacy boards regulate 503A pharmacies. Some states have taken more aggressive enforcement postures following the FDA's shortage resolution; others have been slower to act. A compounding pharmacy operating legally under its state board may still be at odds with FDA federal guidance.

What this means for patients. We strongly recommend that before obtaining compounded semaglutide from any source, you confirm with your prescribing physician that the pharmacy is a currently registered and FDA-inspected 503B outsourcing facility, and that your physician is aware of the current regulatory status. This situation is evolving rapidly, and the legal basis for your specific prescription may have changed since this post was written. The information here is general educational guidance, not legal or medical advice.

Separate from the legal question is a genuine safety concern the FDA raised in a series of communications beginning in 2023. These warnings were about the pharmacological form of semaglutide being used in compounded products, and they deserve to be understood carefully, because the issue is technical but consequential.

The salt form vs. base form problem. FDA-approved Wegovy and Ozempic use semaglutide in its base form, the specific molecular structure that was studied in clinical trials and proven to be safe and effective at documented doses. Many compounding pharmacies were sourcing and using semaglutide sodium, semaglutide acetate, or other salt forms of the drug. Salt forms are chemically different from the base form: they are not bioequivalent, meaning the same numeric dose (in milligrams) does not deliver the same amount of active drug. The FDA issued explicit guidance stating that semaglutide salts had not been shown to be safe or effective and that compounders should not use them. Despite this guidance, salt-form products remained in circulation.

Dosing and labeling errors. The FDA also received adverse event reports related to dosing errors with compounded semaglutide products. Unlike the prefilled auto-injector pens used for Wegovy, compounded vials require the patient to draw up a specific volume using a syringe. Some products were labeled in units rather than milliliters, or vice versa, in ways that led to significant overdoses. Reported adverse effects from semaglutide overdose include severe nausea and vomiting, hypoglycemia, pancreatitis, and hospitalization. The FDA's 2023 safety alert documented multiple hospitalizations and at least some reports of life-threatening events.

Sterility and contamination risks. Compounded injectables that do not meet sterility standards carry risks that oral medications do not. The FDA identified specific compounded semaglutide products through inspection and testing that failed sterility requirements. Injectable contamination can cause infections, abscesses at the injection site, or systemic infections.

What this does not mean. It would be inaccurate to conclude that all compounded semaglutide is dangerous. 503B outsourcing facilities operating under FDA inspection and cGMP standards are held to rigorous sterility and formulation requirements. The FDA's warnings targeted products with identified problems, not a blanket condemnation of the entire compounding industry. A 503B facility using base-form semaglutide, proper sterility protocols, and accurate labeling is a fundamentally different product from a 503A pharmacy using salt-form semaglutide with imprecise dosing instructions.

Understanding the actual differences between compounded semaglutide and Wegovy matters when you are weighing cost against risk.

Active ingredient form. Wegovy uses semaglutide base, the exact form tested in the STEP clinical trials that produced the 15-17% average body weight reduction results that made the drug famous. Compounded semaglutide may use base or salt form, depending on the compounding pharmacy and its raw material sourcing. A reputable 503B compounder should be able to tell you definitively which form they use and provide documentation.

Manufacturing oversight. Wegovy is manufactured in FDA-approved facilities subject to continuous FDA oversight, batch testing, and cGMP compliance. 503B outsourcing facilities are also subject to FDA inspection and cGMP requirements, though they are not equivalent to pharmaceutical manufacturing plants. 503A pharmacies are regulated by state boards and are not subject to FDA inspection or cGMP requirements.

Delivery device. Wegovy is delivered via a prefilled, single-use auto-injector pen. The device is factory-calibrated and does not require any patient measurement or preparation. Compounded semaglutide typically comes as a multi-dose vial that requires the patient to draw up the correct volume using a syringe and needle, reconstitute a lyophilized (freeze-dried) powder in some formulations, or use a separately-filled auto-injector. Each of these steps introduces a potential point of error.

FDA approval. Wegovy carries FDA approval for chronic weight management in adults with BMI ≥ 30, or ≥ 27 with a weight-related comorbidity. Compounded semaglutide has no FDA approval, it is compounded under regulatory authority that permits preparation of non-approved drugs under specific circumstances.

Cost. Wegovy's list price is approximately $1,300-$1,400 per month without insurance. With manufacturer savings cards for commercially insured patients, it can be substantially reduced. Compounded semaglutide from domestic 503B facilities typically runs $200-$500 per month, depending on dose and provider. Prices significantly below $150 per month are a warning sign that should prompt questions about sourcing and quality.

If you are currently using compounded semaglutide, or evaluating a provider that offers it, these are the specific questions and documentation requests that separate reputable programs from risky ones.

Verify the pharmacy is a 503B outsourcing facility. This is the single most important question. 503B facilities are registered with the FDA, subject to FDA inspection, and held to cGMP standards. You can verify a pharmacy's 503B registration on the FDA's publicly available database of registered outsourcing facilities at fda.gov. If the pharmacy is only 503A, regulated by the state board, the oversight standards are considerably lower.

Request a Certificate of Analysis (COA). A legitimate compounding pharmacy using pharmaceutical-grade semaglutide should be able to provide a COA for each batch, documenting the active ingredient identity, purity, potency, and sterility testing results. If a pharmacy cannot or will not provide a COA, that is a significant red flag.

Confirm base form, not salt form. Ask explicitly: 'Does your semaglutide product use semaglutide base, or a salt form such as semaglutide sodium or semaglutide acetate?' A reputable pharmacy will know the answer immediately. If the answer is a salt form, or if the pharmacy cannot answer the question, do not proceed.

Review the dosing instructions carefully. Your product should have clear, unambiguous instructions for the volume to inject (in milliliters), the starting dose, and the escalation schedule. Instructions that use 'units' in a way that could be confused with insulin units are a concern. If anything about the labeling is unclear, call your prescribing physician before injecting.

Confirm physician oversight. You should have a named, licensed physician on your prescription and in your medical records. Telehealth prescribing is legitimate, but you should be able to identify your prescribing physician, contact them with concerns, and expect them to have reviewed your relevant medical history before prescribing.

Houston has one of the densest concentrations of weight loss clinics in the country, and the range of quality in compounded semaglutide programs is wide. Reputable clinics operating in the Houston area, including those in Katy, Sugar Land, and the Heights, have adapted to the regulatory environment by partnering with FDA-registered 503B outsourcing facilities, obtaining baseline lab work before prescribing, and providing physician supervision throughout the program.

Here is what a responsible compounded semaglutide program looks like in practice:

• Initial consultation includes review of your medical history, current medications, and contraindications to semaglutide (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or active pancreatitis are contraindications)
• Baseline labs ordered before prescribing: fasting glucose, HbA1c, thyroid function, comprehensive metabolic panel
• A named, licensed physician on the prescription, not just a nurse practitioner operating without physician oversight
• Clear documentation of which 503B outsourcing facility is supplying the medication, and the ability to provide a COA on request
• An escalation schedule that follows clinical evidence (starting at 0.25 mg weekly, escalating no faster than every 4 weeks)
• Follow-up visits or check-ins built into the program, not one-and-done telehealth prescribing

Red flags that should make you walk away:

• Unusually low prices, under $149 per month in 2026 should prompt serious questions about sourcing
• No lab work before prescribing, ever
• Cannot name the specific 503B pharmacy supplying the medication
• No licensed physician identified on your prescription
• Marketing language that dismisses FDA safety concerns as 'just corporate protectionism'
• Sourcing that appears to be from overseas or from pharmacies that cannot be verified in the FDA's 503B database
• No clear process for handling adverse reactions or side effects

Houston-area clinics operating in Katy and Sugar Land that have invested in proper 503B partnerships and physician-led protocols represent the safer end of the compounded semaglutide market. When evaluating a clinic, asking the specific questions above, rather than accepting general assurances, is the most reliable way to assess program quality.

Given everything above, who is compounded semaglutide actually appropriate for in 2026?

Patients with commercial insurance coverage for Wegovy. If your insurance covers Wegovy, and many employer-sponsored plans now cover it with prior authorization, brand-name is the better option. You get the FDA-approved formulation, the prefilled auto-injector, and documented clinical trial results. Use the manufacturer savings card to reduce out-of-pocket cost further.

Patients without insurance coverage, with limited income options. Brand-name Wegovy's list price remains a significant barrier. For patients who cannot access brand-name Wegovy affordably, compounded semaglutide from a reputable 503B facility with physician oversight is a risk-benefit decision worth having with your doctor, particularly if you have documented obesity-related health conditions that respond to GLP-1 treatment.

Patients already on a stable compounded program. If you have been on compounded semaglutide for several months, are tolerating it well, and your clinic is sourcing from a verified 503B facility using base-form semaglutide, there may be no compelling reason to switch, other than the evolving legal situation, which your physician should be tracking.

Patients who are new to GLP-1 medications. For someone starting GLP-1 therapy for the first time in 2026, it is worth a serious conversation with your physician about whether your insurance can be leveraged to access Wegovy first. The legal uncertainty around compounding, combined with the documented safety concerns about lower-quality products, makes brand-name a lower-risk starting point if it is accessible to you.

The decision is ultimately a clinical and financial one that your physician is best positioned to help you make with full knowledge of your health history, your insurance situation, and their assessment of local compounding pharmacy quality. This guide is intended to give you the background to ask better questions, not to replace that conversation.